HRMY Harmony Biosciences Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1802665 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY19.8%
TTM net income YoY-3.8%
TTM EPS YoY-4.7%
Revenue 3-yr CAGR22.2%
Net income 3-yr CAGR5.8%
Margins
Gross margin74.0%
Operating margin22.2%
Net margin18.1%
FCF margin—
EBITDA margin—
Returns
ROE18.7%
ROA13.3%
ROIC (approx.)36.1%
Asset turnover0.74x
Leverage & solvency
Liabilities / assets27.5%
Debt / equity0.14x
Current ratio3.44x
Interest coverage16.99x
Cash quality & payout
Operating cash flow / net income1.81x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $868.45M | $714.73M | $582.02M | $437.86M | $305.44M |
| Cost of revenue | $198.34M | $156.81M | $121.24M | $83.48M | $55.52M |
| Gross profit | $670.11M | $557.92M | $460.79M | $354.37M | $249.92M |
| R&D expense | $189.59M | $145.82M | $76.06M | $70.89M | $30.37M |
| SG&A expense | $152.54M | $110.35M | $95.29M | $84.02M | $63.91M |
| Operating income | $208.47M | $190.83M | $192.03M | $120.19M | $87.53M |
| Interest expense | $14.65M | $17.50M | $23.76M | $18.80M | $24.19M |
| Pretax income | $215.06M | $191.80M | $173.40M | $104.69M | $37.43M |
| Income tax | $56.38M | $46.31M | $44.54M | -$76.78M | $2.83M |
| Net income | $158.69M | $145.49M | $128.85M | $181.47M | $34.60M |
| EBITDA | — | $191.09M | $192.54M | $120.61M | $87.94M |
| EPS (basic) | 2.76 | 2.56 | 2.17 | 3.07 | 0.60 |
| EPS (diluted) | 2.71 | 2.51 | 2.13 | 2.97 | 0.58 |
| Weighted avg. shares (diluted) | 58.54M | 57.87M | 60.37M | 61.10M | 59.21M |
| Balance sheet | |||||
| Cash & equivalents | $752.50M | $453.27M | $311.93M | $244.53M | $235.06M |
| Short-term investments | $22.84M | $14.19M | $41.80M | $79.33M | — |
| Receivables | $96.79M | $83.03M | $74.14M | $54.74M | $34.84M |
| Inventory | $5.36M | $7.20M | $5.36M | $4.30M | $4.43M |
| Current assets | $907.01M | $579.25M | $451.07M | $400.29M | $284.44M |
| PP&E, net | — | $1.26M | $371,000 | $573,000 | $820,000 |
| Intangibles | $89.42M | $113.26M | $137.11M | $160.95M | $143.92M |
| Total assets | $1.27B | $999.20M | $811.45M | $673.87M | $433.44M |
| Current liabilities | $252.13M | $175.08M | $163.78M | $78.88M | $53.77M |
| Short-term debt | $20.00M | $16.25M | $15.00M | $2.00M | $2.00M |
| Long-term debt | $143.66M | $163.02M | $178.57M | $189.65M | $189.98M |
| Total debt | $163.66M | $179.27M | $193.57M | $191.65M | $191.98M |
| Total liabilities | $401.41M | $340.05M | $344.46M | $271.03M | $246.94M |
| Shareholders' equity | $870.22M | $659.15M | $466.99M | $402.84M | $186.51M |
| Net debt | -$588.84M | -$274.00M | -$118.36M | -$52.89M | -$43.08M |
| Shares outstanding | 57.73M | 57.14M | 56.77M | 59.62M | 58.83M |
| Cash flow statement | |||||
| Operating cash flow | $348.20M | $219.82M | $219.39M | $144.47M | $98.56M |
| Capital expenditure | $310,000 | $1.15M | $312,000 | $172,000 | $298,000 |
| Free cash flow | $347.89M | $218.67M | $219.07M | $144.29M | $98.26M |
| Investing cash flow | -$39.65M | -$67.48M | -$46.44M | -$141.83M | -$100.30M |
| Financing cash flow | -$9.05M | -$11.00M | -$105.55M | $6.84M | $7.42M |
| Depreciation & amortization | — | $267,000 | $514,000 | $419,000 | $416,000 |
| Stock-based compensation | $44.90M | $42.60M | $31.70M | $26.17M | $15.66M |
| Share buybacks | — | — | $100.00M | — | — |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.